MissionIR Articles
-
MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Approval of Charter Amendment
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that on Aug. 17, 2021, the stockholders approved an amendment to the company’s certificate…
-
Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary AI Model Predicts Cancer Outcomes, Leads to New Therapies
AI models of genomic data can predict cancer outcomes, which can then help personalize ovarian cancer treatments Results come from Helomics’ work on the 100,000 Genomes Project in Genomics England’s National Genomic Research Library Model…
-
MissionIRNewsBreaks – Predictive Oncology (NASDAQ: POAI) Announces Adjournment of Special Meeting of Stockholders
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has adjourned its Special Meeting of Stockholders. The meeting was convened on Aug. 10, 2021, at…
-
MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Eyes Expanded Customer Base, Multiple Collaborations, Fulfillment of Researchers’ Needs
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, recently announced that two of its four subsidiaries, Soluble Biotech and TumorGenesis, are expanding their services…
-
MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Stands Distinct in Precision Medicine
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is leveraging its unique, historical database of the drug responses of over 150,000 patient tumors to…
-
MissionIRNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Subsidiaries Showcase Products, Services at BIO Digital
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, participated in the second leg of the Biotechnology Innovation Organization (“BIO”) Digital, a premier international biotech…
-
Predictive Oncology Inc. (NASDAQ: POAI) Companies Build New Labs, Expand Services for New Drug Discoveries
Two of Predictive Oncology’s four subsidiaries are constructing new Good Manufacturing Practices laboratories to offer additional services to customers With its new GMP lab, Soluble Biotech will provide customers formulations that can go directly to…
-
Predictive Oncology Inc. (NASDAQ: POAI) Stands Strong as Innovator, Leader in Precision Medicine
Company plans to use proceeds from direct offering for business development, drug repurposing and discovery and expansion of its laboratory facilities POAI portfolio spans four different subsidiaries, including list of assets rivaling best operators in…
-
MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Bringing Researchers Next-Level Tools for Hard-to-Treat Diseases
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is looking to give oncology drug developers an upper hand, thereby increasing the chances of the…
-
Three Predictive Oncology Inc. (NASDAQ: POAI) Companies Participate in Popular Biotechnology Innovation Organization Digital Conference
More than 3,200 pharmaceutical and biotech companies, plus government and academic organizations attended latest BIO Conference Predictive Oncology’s Helomics, TumorGenesis, Soluble Biotech all attended the virtual conference from June 14-18, 2021 Companies leveraged different components…
-
Predictive Oncology Inc.’s (NASDAQ: POAI) TumorGenesis Partners with Cellevate for New Approach to Ovarian Cancer
Collaboration will use TumorGenesis’ expertise in cancer cell culture growth media in combination with Cellevate’s specialty in emerging field of nanofiber matrixes. Cutting-edge technology can help avoid mistakes in $2.6 billion process of bringing new…
-
MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Building Strong Commercial Pipeline for Unique PeDAL(TM) Platform
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, continues to create value for a growing customer base through its subsidiaries. Researchers from one such…
-
Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Highlights, Q1 Financials Herald Bright Horizon for Company
POAI announced that total stockholders’ equity increased by nearly $33 million to $35.5 million Financial report notes net proceeds of $35.6 million from private placement, direct offering, warrant exercises Company subsidiaries reached several milestone achievements…
-
MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Adds Insight, Strengthens Positioning Through Strategic Board Appointment
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, recently expanded its board of directors with the appointment of Dr. Christina Jenkins. Dr. Jenkins holds…
-
MissionIRNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Helomics CTO Discusses Revolutionizing Drug Discovery in Bell2Bell Podcast
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, was featured in a recent episode of The Bell2Bell Podcast. Predictive Oncology’s newly appointed CEO Mel…
-
Predictive Oncology Inc. (NASDAQ: POAI) Appoints Venture Investor Dr. Christina Jenkins to Board of Directors
POAI appoints strategic advisor, venture investor Dr. Christina Jenkins to board of directors Dr. Jenkins’ experience spans work in capital markets, clinical medicine, public healthcare systems Other roles include current Board Director for Independence Health…
-
Predictive Oncology’s (NASDAQ: POAI) C-Level Leaders Provide Company, Operations Update on New Podcast
Bell2Bell podcast features company CEO, CFO, CTO of Helomics subsidiary POAI is “in probably the best situation we’ve been in since the existence of the company,” reports CFO Company anticipates revenue from its unique PeDAL…
-
MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Advancing Solutions for ‘Personalized Medicine at Its Finest’
Predictive Oncology (NASDAQ: POAI) has made several advances in providing cancer treatment solutions. Its subsidiary, TumorGenesis, “specializes in technology that preserves a patient’s unique cancer tissue biological signatures, thereby allowing researchers to study cancer in…
-
MissionIRNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Helomics Featured in DojoLIVE! Interview
Predictive Oncology’s (NASDAQ: POAI) subsidiary company, Helomics, was recently featured on DojoLIVE!, an engaging podcast and interview forum that brings together technology, business and thought leaders from a wide range of industries. The company’s Chief…
-
MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Featured in Bell2Bell Podcast
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, was featured in The Bell2Bell Podcast, a part of InvestorBrandNetwork’s (“IBN”) sustained effort to provide specialized…
Search Articles
Latest Articles
- MissionIRNewsBreaks – Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Marks Pivotal Moment on Path to 2026 Rare Earth Oxide Production
- PowerBank Corporation (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: 103) Marks Bold Entry Into the Growing Battery Storage Market with 4.99 MW BESS in Ontario
- Soligenix Inc. (NASDAQ: SNGX) Working to Advance Heat-Stable Ricin Vaccine with Promising Efficacy
- New Pacific Metals Corp. (NYSE American: NEWP) (TSX: NUAG) Eyes Bolivia’s Untapped Silver Potential Amid Global Supply Gaps
- MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Q2 2025 Results, Advances TPI 287 Toward Phase 2 GBM Trial